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The coronavirus disease 2019 (COVID-19) has overwhelming healthcare systems globally. To date, a myriad of
therapeutic regimens has been employed in an attempt to curb the ramifications of a severe COVID-19 infection.
Amidst the ongoing pandemic, the advent and efficacious uptake of COVID-19 vaccination has significantly
reduced disease-related hospitalizations and mortality. Nevertheless, many side-effects are being reported after
COVID-19 vaccinations and myocarditis is the most commonly reported sequelae post vaccination. Majority of
these diseases are associated with COVID-19 mRNA vaccines. Various studies have established a temporal
relationship between these complications, yet the causality and the underlying pathogenesis remain hypothet
ical. In this review, we aim to critically appraise the available literature regarding the cardiovascular side effects
of the various mRNA vaccines and the associated pathophysiology.

1. Introduction
The burden that coronavirus disease 2019 (COVID-19) has forced
upon global healthcare systems has necessitated concerted efforts to
wards global immunization programs. As of March 2022, 31 million
COVID-19 vaccines have been administered, with 54% of the global
population having received at least one dose of a COVID-19 vaccine [1].

While studies have reported strong evidence of immunity after a single
dose of a COVID-19 vaccine, vaccination efficacy dramatically increases
after two doses, specifically for the alpha and the delta variants [2,3].
Rare complications of COVID-19 mRNA vaccinations have included
several cardiovascular outcomes such as: myocarditis, pericarditis,
perimyocarditis, myocardial infarctions (MI), coronary thrombosis, and
stress-induced cardiomyopathy (Takotsubo cardiomyopathy) [3].
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Various studies have established a temporal relationship between
vaccination and cardiovascular complications; nevertheless, causality
remains largely inconclusive.
Myocarditis has been the predominant cardiovascular complication
post-COVID-19 vaccination [4]. However, this is not the only instance of
post-vaccine myocarditis historically, as myocarditis cases have been
associated with other vaccinations as well [4]. The Center for Disease
Control and Prevention (CDC) and the U.S. Federal Drug Administration
(FDA) have been monitoring vaccine safety profile and the data sur
rounding post-vaccination complications, common or rare, via a
plethora of vaccine safety monitoring systems: the Vaccine Adverse Ef
fect Reporting System (VAERS), Vaccine Safety Datalink, V-safe, and the
National Healthcare Safety Network. To date, the CDC has confirmed a
total of 2337 reports of myocarditis in VAERS for all vaccines (1990 November 11, 2021), 1969 of which were in people aged 30 and
younger who received COVID-19 mRNA vaccines, which include the
Pfizer-BioNTech and Moderna vaccines [5,6]. Following investigation of
these reports, the CDC and FDA confirmed that 1005 cases met the
criteria for myocarditis, pericarditis, or myopericarditis [5].
The risk of thrombotic events related to COVID-19 vaccines has been
a major concern since reports have surfaced from the U.S., Singapore,
India, and Europe. Although the data is limited, studies have already
been conducted to differentiate clinical presentation of MI from
myocarditis post-COVID-19 vaccinations. In summary, those with postvaccination MI presented at around 24 h post-vaccination, much earlier
than myocarditis at 72 h [7–10]. More importantly, most developed MI

symptoms after the first dose [9,10]. A potential mechanism for
post-vaccination MI could be Kounis syndrome, an allergic hypersensi
tivity reaction to potentially immunogenic components found within
vaccines [9,11]. The vast spectrum of cardiovascular complications
reportedly associated with COVID-19 mRNA vaccinations is delineated
by Fig. 1.
2. Methods
Using the digital databases (PubMed/MEDLINE, CINAHL, and Web
of Science) to search for relevant material, a scoping review was con
ducted by two authors (T.A., T.K.) and articles containing cardiovascular
complications after COVID-19 vaccine were incorporated in this review
in a narrative style. The literature search was don for articles published
between 2020 and 2022. In our search, we used the terms(s): “cardio
vascular sequelae” OR “cardiovascular complications” OR “cardiovas
cular ramifications” OR “myocardial infarction” OR “heart failure” OR
“Takotsubo cardiomyopathy” OR “myocarditis” OR “pericarditis” AND
“COVID-19′′ OR “COVID-19 vaccine” OR “COVID-19 vaccination
programs”.
3. Main text
3.1. Pathophysiology
Primary

infection

with

severe

acute

respiratory

Fig. 1. The various cardiovascular complications that have been reported post-COVID-19 mRNA vaccination if.
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coronavirus 2 (SARS-CoV-2) occurs when the virus’ surface spike S
glycoprotein binds to angiotensin-converting enzyme 2 (ACE2), allow
ing it to enter the cell [12,13]. ACE2 is ubiquitous throughout the body
on the apical surface of epithelial cells, which likely explains the
sequelae of adverse effects reportedly caused by infection [12]. Inter
estingly, with higher concentrations of ACE2 in the lung and heart, this
potentially accounts for the pulmonary and cardiac damage that typifies
a severe systemic COVID-19 infection [12].
While all the different cardiovascular complications have their own
pathophysiological pathways, the COVID-19 mRNA vaccines could
result in these outcomes through similar mechanisms. For instance,
recent studies have implicated vaccines using a nucleoside-modified
mRNA that encodes the viral membrane S glycoprotein of SARS-CoV2. The vaccines instigate the production of antibodies that target the
spike S protein, preventing binding to ACE2, thus conferring both
cellular and humoral immunity [14,15]. The exosomes containing the
spike proteins were also found to stimulate splenic lymphocytes to
secrete interferon (IFN)-γ and tumor necrosis factor (TNF)-α, amplifying
the host inflammatory cell response system and instigating a cascade of
immunological responses that could affect various organ systems,
including the heart [15].
The immunological response induced by the vaccines could explain
the inflammatory processes of myocarditis, pericarditis, and peri
myocarditis. As briefly mentioned earlier, MI induced by the vaccines
could be attributed to Kounis syndrome, which is largely explained by
components within the vaccines known as excipients [11]. Excipients
are pharmaceutical substances found alongside the active substances in
a vaccine. In this case, the COVID-19 vaccine excipients are speculated

to be potentially eliciting hypersensitivity reactions amongst some re
cipients [11]. Different excipients are noted in various vaccine formu
lations; polyethylene glycol (Pfizer-BioNTech vaccine); polyethylene
glycol and tromethamine/trometamol (Moderna vaccine); polysorbate
80 (Johnson & Johnson vaccine); polysorbate 80 and disodium ethyl
enediaminetetraacetic acid dihydrate (Sputnik V vaccine); and disodium
hydrogen phosphate, sodium dihydrogen phosphate monohydrate, and
sodium chloride (Sinovac-Coronavac vaccine) [11]. An IgE-mediated
hypersensitivity reaction concurrent with an acute coronary syndrome
(ACS) or MI is termed Kounis syndrome [16]. This syndrome is
accompanied by clinical and laboratory evidence of MI whose more
predominant etiologies have been excluded and instead attributed to a
hypersensitivity reaction characterized by release of inflammatory me
diators such as histamine, neutral proteases (tryptase, chymase, and
cathepsin-D), arachidonic acid metabolites, platelet-activating factor
(PAF), cytokines, and chemokines released during mast-cell degranula
tion and by immune cells such as T-cells, B-cells, plasma cells, and
macrophages [11,16,17]. The mechanism of action of COVID-19 mRNA
vaccines is elucidated in Fig. 2.
In addition to precipitating ischemic events, there have been reports
of broken hearts. A recent case of post-COVID-19 vaccination Takotsubo
syndrome was diagnosed and reported [18,19]. Takotsubo syndrome
has been described to be primarily attributed to an identifiable physical
or emotional stressor, presents similarly to ACS, and most commonly
affects post-menopausal women. It is a result of myocardial wall motion
abnormalities in a distribution that is covered by a single coronary ar
tery and nearly always presents with left ventricular wall dysfunction
[19–21].
Its
pathophysiology
is
predominated
by

Fig. 2. The mechanism of action of COVID-19 mRNA vaccines. TCR: T-cell receptor; MHC-I: major histocompatibility complex I; TAP: trasporter associated with
antigen processing; MHC-II: major histocompatibility complex II; APC: antigen presenting cell.
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catecholamine-mediated
dysfunction
and
its
pathogenesis
post-COVID-19 vaccination is currently hypothesized to be mediated by
the hypersensitivity response seen in Kounis syndrome [19].

continued to experience chest discomfort [25]. While their follow-up is
ongoing, median length of stay for all myocarditis cases was around 2–3
days with a range of 2–10 days [25]. Treatment of myocarditis cases
amongst the studies included non-steroidal anti-inflammatory drugs
(NSAIDs), colchicine, aspirin and steroids [25–27]. Beta blockers and
ACE inhibitors were administered in some cases for left ventricular
dysfunction as a cardioprotective therapy to prevent positive remodel
ing of the heart [7,24].
As of March 2022, the CDC reported an incidence of 4.8 cases of
myocarditis per one million post-COVID-19 mRNA vaccines, with a
predominance in young males [27]. The curtailed duration between
COVID-19 vaccination and symptom onset is supplanted by the elevated
incidence of myocarditis [27]. Notably, many studies have acknowl
edged limitations in these statistics, hypothesizing missed cases of
post-vaccine myocarditis that would underestimate the reported inci
dence [28].
The incidence of myocarditis following the mRNA vaccines was
higher after the second dose, especially in adolescent and young adult
males within a week of vaccination [7]. The CDC collected this using
data from the U.S.A database of healthcare encounters consisting of
more than 900 hospitals between March 2020 and March 2022,
revealing that patients infected with COVID-19 had 15.7 times the risk
of myocarditis compared to noninfected patients [8]. The risk ratio
varied across age (7.0 for aged 16–39 and >30.0 for those < 16 and > 75
years old) and gender (13.8 for males, 17.8 for females) [8]. In another
study from Israel, the risk ratio of myocarditis associated with mRNA
vaccination and COVID-19 infection were compared (3.24 vs 18.28,
respectively), showing that the risk of myocarditis is higher with
infection than vaccination [8]. In regards to prognosis in this cohort, no
long-term data is yet available.

3.2. Discussion
The current review aims to consolidate the data surrounding the
various adverse cardiovascular events––myocarditis, perimyocarditis,
pericarditis, MI, coronary thrombosis, or Takotsubo syndro
me––associated with COVID-19 mRNA vaccinations (see Tables 1, 2, 3).
The mean age of the participants hovered at 56 ± 8.7 years, with a
standard deviation (SD) of 8.4 years. There was a slight male prepon
derance, with 68.4% males and 31.6% females. More notably, females
with any reported adverse cardiovascular event post-vaccination were,
on average, older than their male counterparts (62.3 years vs 58.8 years,
SD: 8.2 years, 95% confidence interval [CI]: 52.7–70.3 years, P < 0.05).
3.3. Myocarditis
We included a total of 7 studies (6 case series and 1 case report)
between August and November 3rd, 2021: a total of 102 cases of
myocarditis post-mRNA vaccination (Table 1). The vaccinations
received in the studies were as follows: 57 received the Pfizer BioNTech
vaccine, 44 received Moderna, and 1 Comirnaty. Most cases were male,
including the single case report, with an age range of 19–71 years old.
The most common comorbidities were hypertension, smoking, and a
previous history of coronary artery disease, all of which demonstrated a
worse prognosis. Interestingly, patients with comorbidities, specifically
hypertension and active smoking, exhibited significantly lower antibody
titers following COVID-19 vaccination, which could contribute to an
increased likelihood of post-vaccine complications [22]. Another study
sheds further light by promoting smoking cessation prior to vaccination
to ameliorate the efficacy of the BioNTech Pfizer vaccine [23].
Of the 102 cases with myocarditis, four were PCR-positive after
vaccination. One study, pooling cases of myocarditis from the USA,
Israel, Singapore, and a few other countries, demonstrated that 83% of
the patients developed myocarditis symptoms only after the second
vaccine dose [9]. Additionally, a retrospective case series analyzing data
from the Mayo Clinic COVID-19 Vaccine Registry elucidated that all
seven cases occurred after the second dose [7]. Other studies that have
reported myocarditis symptoms occurring post-second dose of
COVID-19 mRNA vaccines reported rates hovering between 40% and
100%. Among the included studies, the median time between vaccina
tion and onset of symptoms was 1–3 days [24]. However, one study
reported a mean time of onset of 15.4 days, with a range of 3–28 days
[24]. The study included case reports from Switzerland using the
Regional Pharmacovigilance Center (RPVC) internal database for cases
of myocarditis, perimyocarditis, and pericarditis temporally related to
COVID-19 mRNA vaccination [24].
Most cases of myocarditis post-vaccination presented with elevated
cardiac troponin levels along with simultaneous elevations in C-reactive
protein (CRP), brain natriuretic peptide (BNP) or N-terminal pro
hormone BNP (NT-proBNP) [7,9,24]. Interestingly, abnormal electro
cardiogram findings were seen in a few patients. Fourteen myocarditis
cases presented with a left ventricular ejection fraction (LVEF) of < 50%
[7–10, 25, 26]. Abnormal cardiac magnetic resonance imaging (MRI)
with late gadolinium enhancement and edema were observed in 51 cases
[7,9,24–27]. Late gadolinium enhancement was found in 41% of the
patients in the subepicardial layer, 14% in the mid-myocardial layer,
and 24% in both layers [9]. The same study found edema in 21% of cases
within the subepicardial layer, 17% within the mid-myocardial layer,
and 24% within both layers [9]. These findings further substantiate the
presence of epicardial and myocardial inflammation in the aftermath of
vaccination.
Almost all of the cases experienced a prompt recovery, with no re
sidual cardiac dysfunction. However, in one study, seven patients

3.4. Pericarditis
Cases of post-vaccination pericarditis were reported in studies from
Switzerland and the United States, both of which compared the inci
dence with that of post-COVID-19 myocarditis [24,27]. A total of 40
pericarditis cases were recorded, with 75% males and a median age of
59–60 years old. While pericarditis presents similarly to myocarditis,
pericarditis had a higher incidence in men with old age. Hypertension,
diabetes mellitus and a previous history of coronary artery disease were
the top three comorbidities.
The mean time from vaccination to onset of symptoms was 6.5 and
20 days [24,27]. It can be explained by difficulty in diagnosis of peri
carditis due to less specific symptoms. In the Switzerland study, three
cases were reported, with one presenting with unclear symptoms and
vague diagnostic criteria score due to self-reporting [24]. This
less-than-optimal clinical evaluation could be attributed to recall bias,
which would contribute to limitations within the studies and lead to
difficulty in evaluating temporality between the vaccine and its
complications.
In the United States, 59.5% of pericarditis occurred after the second
dose of the vaccine [27]. Three patients had an LVEF of < 50%,
increased troponin levels, and abnormal ECGs. Length of hospitalization
ranged from 0 to 11 days. Treatment included a regimen of NSAIDs,
colchicine, and steroids. However, complete resolution of symptoms was
reported in only 18.9% of pericarditis cases [27].
3.5. Perimyocarditis
In a study, cases of perimyocarditis were identified and reported in
association with the COVID-19 vaccines [24]. Data from a regional
pharmacovigilance center in Switzerland included perimyocarditis
diagnosed in line with the diagnostic criteria of the European Society of
Cardiology [24]. Nine cases of perimyocarditis were reported with a
median age of 57 years (range 17–88). Seven of the cases were males
(78%) with a median age of 23 years (range 17–86) [24]. Six patients
4
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Table 1
Details of studies reporting myocarditis cases post-COVID-19 mRNA vaccine. Study cohort characteristics, comorbidities, clinical presentation, diagnostic evaluation, and outcome are all summarized.
Case Series

Myocarditis Following COVID19 mRNA Vaccine: A Case
Series and Incidence Rate
Determination

Acute myocardial
infarction and
myocarditis
following COVID19 vaccination

Myocarditis and
pericarditis in association
with COVID-19 mRNAvaccination: cases from a
regional
pharmacovigilance center

Myocarditis Following
Immunization With
mRNA COVID-19
Vaccines in Members of
the US Military

Patients With
Acute Myocarditis
Following mRNA
COVID-19
Vaccination

Myocarditis and
Pericarditis
After
Vaccination for
COVID-19

Case Report

Acute Myocarditis after
COVID-19 vaccination: A
case report

Study

Perez et al. [7]

Aye et al. [9]

Istampoulouoglou et al.
[24]

Montgomery et al. [25]

Kim et al. [26]

Diaz et al. [27]

Study

Schmitt et al. [31]

7
6 (86%)
44 (22–71)

42
38 (91%)
21 (17–30)

5
3 (60%)
34 ( 20–44)

23
23 (100%)
25 (20–51)

4
3 (75%)
38.3 (23–70)

20
15 (75%)
36 (26.3–48.3)

Characteristics
Case, n
Gender
Age

1
Male
19

Pfizer-BioNTech: 3 (42%)
Moderna: 4 (57%)

Pfizer BioNTech:
35 (83%) Moderna:
6 (14%)

Moderna: 4 (80%)
Comirnaty: 1 (20%)

Pfizer BioNTech: 7 (30%)
Moderna: 16 (70%)

Pfizer BioNTech: 2
(50%) Moderna: 2
(50%)

Pfizer
BioNTech: 9
(45%)
Moderna: 11
(55%)

5 (72%)
3 (42%)
3 (42%)
2 (29%)
1 (14%)
1 (14%)

4 (10%)
4 (10%)
–
2 (5%)
–
–
–

–
–
–
–
–
–
–

–
–
–
–
–
–
3 (13%)

1 (25%)
–
1 (25%)
1 (25%)
–
–
–

5 (25%)
–
2 (10%)
–
1 (5%)
–
–

–

–

–

0

–

–

3 (1–13)

3 (2–3)

15.4 (3–28)

2 (0.5–4)

2.75 (1–5)

3.5 (3–10.8)

Characteristics
Cases, n
Male, %
Medianage (range),
years
Vaccine type

5

Comorbidities
Hypertension
Hyperlipidemia
Diabetes Mellitus
Smoking
Previous hx of CAD
FHx of CAD
Prior COVID-19
infection
COVID-19 PCR
positive
Presentation
Time between last
vaccine and

Second dose of PfizerBioNTech

–
–
–
–
–
–
–
No
1

(continued on next page)
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Comorbidities
Hypertension
Hyperlipidemia
Diabetes mellitus
Smoking
Previous hx of CAD
FHx of CAD
Prior COVID-19
infection
COVID-19 PCR
positive
Presentation
Time between last
vaccine and
symptoms onset,

Vaccine type

T. Almas et al.

Table 1 (continued )
Case Series

median days
(range)
Symptoms postsecond dose
Chest pain
Other symptoms (e.
g., myalgia,
fatigue, fever)
Diagnostic
Evaluation
Elevated troponin
Elevated BNP or NTproBNP
Elevated CRP
Abnormal ECG

Myocarditis Following COVID19 mRNA Vaccine: A Case
Series and Incidence Rate
Determination

Acute myocardial
infarction and
myocarditis
following COVID19 vaccination

Myocarditis and
pericarditis in association
with COVID-19 mRNAvaccination: cases from a
regional
pharmacovigilance center

Myocarditis Following
Immunization With
mRNA COVID-19
Vaccines in Members of
the US Military

Patients With
Acute Myocarditis
Following mRNA
COVID-19
Vaccination

Myocarditis and
Pericarditis
After
Vaccination for
COVID-19

2 (40%)

20 (87%)

4 (100%)

16 (80%)

–
–

–
–

4 (80%)
2 (40%)

100%
–

1 (25%)
4 (100%)

–
–

–
4/5 (80%)

–
–

4 (60%)
–

23 (100%)
–

4 (100%)
2 (50%)

19 (95%)
–

–
5/7 (71%)

–
27 (64%)

–
3 (60%)

–
19 (83%)

3 (75%)
4 (100%)

–
9 (45%)

Abnormal MRI
Abnormal
echocardiogram
LVEF < 50%
Outcome
Symptoms resolved

3/6 (50%)
3/6 (50%)

32 (76%)
–

3 (60%)
–

8 (35%)
4 (17%)

4 (100%)
–

–
–

3/6 (60%)

–

1 (20%)

4 (17%)

1 (25%)

5 (25%)

7 (100%)

–

5 (100%)

16 (69%)

100%

13 (65%)

Median length of
hospitalization,
days (range)
Treatment regimen

2 (2–4)

–

6 (3–10)

–

–

2 (2–3)

Combination of steroids (2/7,
29%), NSAIDs(2/7, 29%), and
colchicine (5/7, 71%) which is
known to modulate multiple
anti-inflammatory pathways
[16]. None received IVIG. ACE
inhibitors and β-blockers were
prescribed for patients with LV
dysfunction.

Discharged on
NSAIDs 24/42
(57%), colchicine
13/42 (31%),
aspirin 3/42 (7%),
β-blockers 6/42
(14%)

Cardioprotective therapy
with an ACE inhibitor
(60%) followed by a
β-blocker (40%)

Cardiac symptoms
resolved within 1 week of
onset (16 patients). Seven
patients continued to
have chest discomfort at
the time of this report;
follow-up is ongoing.

NSAIDs and
colchicine, with 1
patient receiving
corticosteroids

NSAIDs 75%,
and colchicine
45%

Abnormal MRI
Abnormal
echocardiogram
LVEF < 50%
Outcome
Symptoms
resolved
Length of
hospitalization
Follow-up and
medications
received for
myocarditis

Acute Myocarditis after
COVID-19 vaccination: A
case report

Yes
No
Yes

Yes
Yes
Yes
Yes; PR depression in
inferior leads and a
persistent concave ST
elevation without
reciprocal depression
Yes
–
No
Yes
–

At 1 month follow-up, the
patient remained
asymptomatic, with
normal ECG and
echocardiogram. No
medication was
prescribed.

Hx: history, CAD: coronary artery disease, FHx: family history, PCR: polymerase chain reaction, brain natriuretic peptide (BNP), N-terminal prohormone BNP (NT-proBNP), CRP: C-reactive protein, ECG: electrocar
diogram, MRI: magnetic resonance imaging, LVEF: left ventricular ejection fraction, NSAIDs: nonsteroidal anti-inflammatory drugs, IVIG: intravenous immunoglobulin, ACE: angiotensin converting enzyme, LV: left
ventricle.
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35 (83%)

symptoms onset
(days)
Symptoms postsecond dose
Chest pain
Other symptoms
(e.g., myalgia,
fatigue, fever)
Diagnostic
Evaluation
Elevated troponin
Elevated BNP or
NT-proBNP
Elevated CRP
Abnormal ECG

6

1 (14%)

Case Report

T. Almas et al.

Biomedicine & Pharmacotherapy 149 (2022) 112843

Table 2
Studies of pericarditis & perimyocarditis cases post-COVID-19 mRNA vaccine with study cohort characteristics, comorbidities, clinical presentation, diagnostic
evaluation, and outcomes all summarized.
Case Series

Pericarditis

Author
Characteristics
Cases, n
Male, %
Median age (range),
years
Vaccine type
Comorbidities
Hypertension
Hyperlipidemia
Diabetes Mellitus
Smoking
Previous hx of CAD
FHx of CAD
Prior COVID-19 infection
COVID-19 PCR positive
Presentation
Median time between
last vaccine and
symptoms onset, days
(range)
Symptoms post seconddose
Chest pain
Other symptoms (e.g.,
myalgia, fatigue,
fever)
Diagnostic Evaluation
Elevated troponin
Elevated BNP or NTproBNP
Elevated CRP
Abnormal ECG
Abnormal MRI
Abnormal
echocardiogram
LVEF < 50%
Outcome
Symptoms resolved
Median length of
hospitalization, days
(range)
Treatment regimen

t

Perimyocarditis

Myocarditis and pericarditis in association
with COVID-19 mRNA-vaccination: cases from
a regional pharmacovigilance center

Myocarditis and pericarditis in
association with COVID-19 mRNAvaccination: cases from a regional
pharmacovigilance center

Myocarditis and
Pericarditis After
Vaccination for
COVID-19

Istampoulouoglou et al. [24]

Diaz et al. [27]

Istampoulouoglou et al. [24]

3
2 (67%)
61 (33–71)

37
27 (73%)
59 (46–69)

9
7 (78%)
57 (17–88)

Pfizer-BioNTech: 1 (33.33%)
Moderna: 1 (33.33%)

mRNA-1273: 12 (32%)
BNT162b2: 23 (62%)
Ad26. COV2. S: 2 (5%)

Moderna: 6 (67%)Comirnaty: 3 (33%)

1 (33%)
–
–
–
–
–
–
–

18 (48.6%)
–
4 (10.8%)
–
4 (10.8%)
–
–
–

3 (33%)
–
–
–
2 (22%)
–
–
–

6.5 (1–14)

20 (6.0–41.0)

4.67 (<1–17)

–

22 (59.5%)

7 (78%)

1 (33%)
1 (33%)

–
–

56%
20%

2 (67%)
–

0
–

8/9 (89%)
–

–
2 (67%)
–
–

–
14 (37.8%)
–
–

–
7/8 (88%)
6/7 (86%)
–

–

3 (8.1%)

–

2 (67%)
7.5 (0–11)

7 (18.9%)
1 (1–2)

3 (33%)
6 (3–10)

For the management of pericarditis,
all three patients received antiinflammatory therapy with ibuprofen
and colchicine.

Treated with NSAIDs
48.6%, colchicine
54.1%, and systemic
steroids 10.8%

The most used treatment was a
cardioprotective therapy with an ACE inhibitor
or a β-blocker (each 44%), followed by a
combination of these two drugs or ibuprofen as
anti-inflammatory therapy (each 33%).

Hx: history, CAD: coronary artery disease, FHx: family history, PCR: polymerase chain reaction, brain natriuretic peptide (BNP), N-terminal prohormone BNP (NTproBNP), CRP: C-reactive protein, ECG: electrocardiogram, MRI: magnetic resonance imaging, LVEF: left ventricular ejection fraction, NSAIDs: nonsteroidal antiinflammatory drugs, ACE: angiotensin converting enzyme, LV: left ventricle.

(67%) received the Moderna vaccine, and three received Comirnaty
[24]. Hypertension was reported in three patients (33%) and a previous
history of CAD in two (22%). The mean time from vaccination to
symptom onset was 4.7 days, with seven (78%) cases presenting after
second dose [24]. Five patients (56%) presented with chest pain and two
(22%) presented with nonspecific symptoms such as myalgia, fever, and
other flu-like symptoms [24]. Abnormal troponin levels were observed
in eight patients (89%), significant ECG findings in seven (77%), and
noteworthy MRI findings in six (67%). Notably, symptoms fully resolved
in only three patients (33%), among which the median length of stay
was 6 days. The treatment regimen for these cases included an ACE
inhibitor (administered to 4 patients) or a β-blocker (4 patients), fol
lowed by combination therapy with an ACE inhibitor and β-blocker or
ibuprofen as anti-inflammatory therapy [24].

3.6. Myocardial infarction
A total of two case series with a total of 37 cases documenting cases
of MI post-COVID-19 mRNA vaccination were studied as demonstrated
in Table 3 [9,10]. Males were predominantly affected making up 78% of
cases with a mean age of 55 years in one study and 65 in the other,
interestingly this gender distribution was noted to be similar to the de
mographic most vulnerable to COVID-induced myocarditis [9,10].
Comorbidities found within the two studies included hypertension
(62%), hyperlipidemia (57%), diabetes mellitus (51%), and active
smoking (35%), all amongst the most significant risk factors for the
complication of MI [9,10].
One of the studies pooled data from a retrospective cohort of cases of
myocarditis and MI found in patients post-COVID-19 mRNA vaccination
7
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Table 3
Studies of MI (myocardial infarction), Coronary Thrombosis & Takotsubo syndrome cases post-COVID-19 mRNA vaccine.
Case Series - AMI

Acute
Myocardial
Infarction
Within 24 h
After COVID19 Vaccination

Acute myocardial
infarction and
myocarditis following
COVID-19 vaccination

Case Report Coronary
thrombosis

Acute Coronary Tree
Thrombosis After
Vaccination for COVID-19

Case Report Takotsubo
syndrome

Takotsubo syndrome
after receiving the
COVID-19 vaccine

Author

G. Sung et al.
[10]

Aye et al. [9]

Author

Tajstra et al. [18]

Author

Fearon et al. [19]

2
1 (50%)
55 (42–68)

35
28 (80%)
65 (59–74)

Characteristics
Case
Gender
Age

1
Male
86

Characteristics
Case
Gender
Age

1
Female
73

mRNA-1273
vaccine: 2
(100%)

Pfizer BioNTech:30
(86%)Moderna: 1 (1%)

Vaccine type

Pfizer–BioNTech vaccine

Vaccine type

1 (50%)
2 (100%)
–
1 (50%)
1 (50%)

22 (63%)
19 (54%)
18 (51%)
12 (34%)
9 (26%)

Comorbidities
Hypertension
Hyperlipidemia
Diabetes Mellitus
Smoking
Previous hx of CAD

–
–
–
–
Yes

FHx of CAD
Prior COVID-19
infection
COVID-19 PCR
positive
Presentation
Time between last
vaccine and
symptoms onset,
median days
(range)
Symptoms postsecond dose
Chest pain
Other symptoms (e.
g., myalgia,
fatigue, fever)
Diagnostic
Evaluation
Elevated troponin
Elevated BNP or
NT-proBNP
Elevated CRP
Abnormal ECG

1 (50%)
–

–
–

–

–

2 (1–3)

1 (1–2) days

0

6/18 (33%)

–
–

–
–

2 (100%)
–

–
–

–
1 (50%)

–
20 (57%)

Abnormal MRI
Abnormal
echocardiogram

–
–

LVEF < 50%
Outcome

–

Characteristics
Cases, n
Male sex, %
Median age
(range), y
Vaccine type
Comorbidities
Hypertension
Hyperlipidemia
Diabetes mellitus
Smoking
Previous hx of CAD

FHx of CAD
Prior COVID-19
infection
COVID-19 PCR
positive
Presentation
Time between last
vaccine and
symptoms onset
(days)

–
–

Symptom postsecond dose
Chest pain
Other symptoms
(e.g., myalgia,
fatigue, fever)
Diagnostic
Evaluation
Elevated troponin
Elevated BNP or
NT-proBNP
Elevated CRP
Abnormal ECG

No

–
–

Abnormal MRI
Abnormal
Echocardiogram
present

–

LVEF < 50%
Abnormal
coronary
angiography

–
Yes, acute ST-segment
elevation myocardial
infarction of the inferior
wall
–
Occlusions/distal
embolization found in 3
arteries

–

< 1 (30 min)

No
Yes

–
–
–
–

Comorbidities
Hypertension
Hyperlipidemia
Diabetes mellitus
Smoking
Previous hx of
CAD
FHx of CAD
Prior COVID-19
infection
COVID-19 PCR
positive
Presentation
Time between last
vaccine and
symptoms onset
(days)
Symptoms postsecond dose
Chest pain
Other symptoms
(e.g., myalgia,
fatigue, fever)
Diagnostic
Evaluation
Elevated troponin
Elevated BNP or
NT-proBNP
Elevated CRP
Abnormal ECG

Abnormal MRI
Abnormal
echocardiogram
LVEF < 50%
Outcome

Moderna COVID-19
vaccination

–
–
–
–
–
–
–
–

< 1 day (17 h after
vaccination)

Yes
No

Yes
–
–
Electrocardiogram had
ST wave changes
concerning for
inferolateral ischemia
and new poor anterior R
wave progression
–
–

Yes

(continued on next page)
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Table 3 (continued )
Case Series - AMI

Acute
Myocardial
Infarction
Within 24 h
After COVID19 Vaccination

Acute myocardial
infarction and
myocarditis following
COVID-19 vaccination

Case Report Coronary
thrombosis

Acute Coronary Tree
Thrombosis After
Vaccination for COVID-19

Underwent PCI

2 (100%)

21 (60%)

Outcome

Symptoms resolved

2 (100%)

–

Patient underwent
PCI

Median length of
hospitalization,
days (range)
Treatment regimen

4.5 (2–7)

–

Symptoms resolved

Initiated on
guidelinedirected
medical
therapy

Discharged on:25/26
(96%) Aspirin, 22/29
(76%) on P2Y12
inhibitor, 20/26 (77%) on
β-blockers, 14/26 (54%)
on ACE inhibitor, 28/35
(80%) on statins, direct
anticoagulants 5/35
(14%), CCBs 4/35 (11%),
nitrates 3/35 (9%),
diuretics 8/35 (23%)

Length of
hospitalization

Primary PCI of the RCA
with manual aspiration
thrombectomy was
performed, along with
coronary balloon
angioplasty and
glycoprotein IIb/IIIa
receptor inhibitor
(eptifibatide)
administration, resulting in
coronary flow
improvement.
On January 30, 2021, the
patient died.(3 days after
symptoms developed)
3

Case Report Takotsubo
syndrome

Takotsubo syndrome
after receiving the
COVID-19 vaccine

Symptoms
resolved
Length of
hospitalization

Yes
8

Hx: history, CAD: coronary artery disease, FHx: family history, PCR: polymerase chain reaction, brain natriuretic peptide (BNP), N-terminal prohormone BNP (NTproBNP), CRP: C-reactive protein, ECG: electrocardiogram, MRI: magnetic resonance imaging, LVEF: left ventricular ejection fraction, ACE: angiotensin converting
enzyme, PCI: percutaneous coronary intervention, RCA: right coronary artery, CCB: calcium channel blockers.

resulting in the unduly cardiac events amongst the recipients [9,31].
While the pathogenesis of MI post-COVID-19 mRNA vaccination re
mains elusive, Kounis syndrome is hypothesized to be a contributing
factor or even etiology [9,10,14]. Older patients with underlying
comorbidities such as hypertension and a previous history of CAD are
more vulnerable to high stressors, and this could explain the cases of MI
post-vaccination [31]. Note that these theories are different from those
of myocarditis induced by COVID-19 vaccines, which were mostly
attributed to non-inflammatory responses between vaccine and cardiac
cell proteins [32].
A recent paper reported the case of a 86-year-old male who collapsed
within 30 min after receiving the vaccination, with ECG showing STelevations in the inferior wall. Investigations revealed a triple coro
nary artery thrombosis after the first dose of the Pfizer–BioNTech vac
cine, which was soon followed by hemodynamic instability [18].
Coronary angiography showed distal blockage in the left anterior
descending artery, the first diagonal branch, and right coronary artery
[18]. The patient was treated with primary percutaneous coronary
intervention of the right coronary artery with aspiration thrombectomy,
coronary balloon angioplasty, and administration of a eptifibatide,
glycoprotein IIb/IIIa receptor inhibitor [18]. The patient remained
hospitalized for three days and expired shortly thereafter [18]. It is of
significance to note that the patient in the study had a previous history of
prostate cancer for which he received treatment in 2006 through sur
gical resection and radiotherapy [18]. At the time of vaccination, he was
on an androgen receptor inhibitor, and his medical history included
paroxysmal atrial fibrillation for which he was taking apixaban twice
daily [18]. In this context, a concoction of risk factors could have
precipitated his clinical deterioration, contributing to a hypercoagulable
state and thus leading to coronary thrombosis. Nevertheless, this would
not explain the acute presentation post-vaccination. While not much can

in Singapore, and included these cases in a systematic review of similar
cases from the USA, Israel, India, and other countries [9]. The median
time noted between vaccination and onset of symptoms was approxi
mately 1–2 days, with 33% of documented cases occurring post-second
vaccination in one of the studies alluding to the differentiation of MI
cases post vaccination occurring post first dose of the vaccine in com
parison to myocarditis cases occurring more commonly post second dose
of the vaccine [9]. Troponin levels were elevated in most cases, with
ST-elevations found in 57% of patients in one of the studies [9]. The ST
elevations were noted in anterior leads in 20% of cases, lateral leads in
6%, and inferior leads in 20%. Mean LVEF was 50% (range 40–55%),
with 89% presenting with regional wall motion abnormalities on
transthoracic echocardiogram (TTE) [9]. Within the same study, 66% of
cases received culprit-vessel percutaneous coronary intervention (PCI):
37% left anterior descending (LAD) artery, 20% right coronary artery
(RCA), 5% left circumflex (LCX) artery, and 5% other vessels [9,10].
The patients in the retrospective cohort of 35 patients were dis
charged on NSAIDs, colchicine, direct oral anticoagulants, β blockers,
and statins, which resulted in a prompt abatement of their clinical
symptoms [9]. Effective treatment with the aforementioned regimen
lends further evidence to Kounis syndrome as a plausible pathophysio
logical explanation for the observed inflammatory phenomenon [14].
The other study reported two patients that underwent PCI to the LCX
[10]. Both patients remained symptom free upon discharge and the
median hospital stay was 4.5 days [10].
One hypothesis for the development of MI post-COVID-19 vaccine
states that vaccines induce an autoimmune reaction response against
platelets, a clinically similar phenomenon to autoimmune heparin
induced thrombocytopenia. [29,30] Other studies have postulated that
the stress and emotional turmoil that can accompany receipt of the
COVID-19 vaccine amongst adults could lead to a demand-ischemia,
9
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be ascertained from a single case report, the curtailed intervening period
between vaccination and onset of symptoms alludes to a link between
the two, with Kounis syndrome remaining the predominant unifying
theory for the pathogenesis at hand.

outcomes. Future studies are necessary to confirm the true relationship
and strength of association between the COVID-19 mRNA vaccines and
cardiovascular complications reported in this review. Further research is
warranted on the extent to which a SARS-CoV-2 infection can itself elicit
adverse downstream cardiovascular effects [18–23, 25–28]. While the
race towards the development of novel, all-encompassing vaccinations
runs astride the pharmaceutical giants, it is pivotal to factor in the
ramifications that these vaccines can elicit. Nevertheless, the true
challenge arises from a concoction of the paucity of data that exists, and
the inability to identify the true etiologies of these cardiovascular out
comes in the aforementioned patient cohorts.

3.7. Takotsubo syndrome
Many cases of Takotsubo cardiomyopathy have been reported in
association with COVID-19 infection [21]. Yet perhaps more interesting
is that, since the commencement of COVID-19 vaccination regimens,
there has been an increasing incidence of Takotsubo syndrome. A recent
study reported the case of a 73-year-old woman with a history of chronic
kidney disease (CKD) and hypertension who was admitted 17 h after
Moderna’s COVID-19 vaccination on suspicion of non-ST elevation
myocardial infarction: a troponin of 0.22 ng/mL, creatinine 2.0 mg/dL,
BNP > 70,000 pg/mL, procalcitonin 0.61 ug/L, no signs of infection,
and ECG findings indicative of inferolateral ischemia and poor R wave
progression [19]. TTE demonstrated LV apical ballooning, an EF of 20%,
with mild mitral regurgitation, and severe right ventricular dysfunction
with functional tricuspid regurgitation [19]. She was diagnosed with
Takotsubo syndrome and was subsequently treated for acute heart
failure [19,20]. Repeat TTE at three days showed marked improvement
in her biventricular function and an EF of 35–40%, and by discharge on
day 8 the heart failure had resolved.
While the ACE2 receptor has been implicated in the pathogenesis of
COVID-19-induced myocardial injury leading to Takotsubo syndrome,
the mechanism underlying the vaccine-induced entity of Takotsubo
syndrome is not expected to herald comparable levels of cardiac injury
[19]. Rather than direct damage to the heart as in infection, it was
postulated that the vaccine may stimulate a systemic inflammatory
response that merely sensitizes patients to catecholaminergic effects,
resulting in an imbalance between sympathetic and parasympathetic
drives that manifests as Takotsubo cardiomyopathy [19,21,33,34].
Furthermore, it has been postulated that the overwhelming emotional
turmoil and stress fomented by the uptake of COVID-19 vaccination can
herald even greater catecholamine release, which can precipitate the
myocardial stunning that is observed in Takotsubo cardiomyopathy.

6. Conclusion
This review highlights various cardiovascular complications associ
ated with COVID-19 mRNA vaccines in order to emphasize that early
recognition of similar presentations can lead to prompt treatment and
improved patient outcomes. While the severity of these cases cannot be
understated, the present review reinforces that the benefits and effec
tiveness of the COVID-19 mRNA vaccines trump their risk of the afore
mentioned sequelae.
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4. Summary
To summarize, several studies reporting cases of cardiovascular side
effects secondary to mRNA COVID-19 vaccines have been discussed.
These include myocarditis, perimyocarditis, pericarditis, MIs, and
Takotsubo syndrome [21–32]. Most pertinently, the time between
vaccination and the onset of symptoms varied between complications.
The reported cases shared certain predisposing risk factors, such as
hypertension, active smoking and a previous history of CAD [14–21].
The reported cases were mainly males with age variation. Notably,
myocarditis predominantly affected younger males while pericarditis
was observed in older males [24,27]. While myocarditis is the highest
reported cardiovascular ramification, other serious complications are
also being increasingly reported [3–12, 27, 31–33]. Nevertheless, the
strength of association between the mRNA COVID-19 vaccines and
cardiovascular complications is temporal, and any causality or under
lying pathogenesis remain unclear and the subject of a pathophysio
logical conundrum.
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5. Future perspectives
This review incorporated numerous studies reporting cardiovascular
sequelae of COVID-19 mRNA vaccines. Although post-vaccination
myocarditis is mild and self-resolving, other serious complications
such as thrombosis can incur adverse outcomes in the patients. The aim
should be close monitoring for those who present with similar symptoms
after COVID-19 mRNA vaccination. Nonetheless, we cannot rule out
whether mRNA vaccines were the sole cause of the cardiovascular
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